Crispr Therapeutics (CRSP) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $4.1B
- As of Nov 13, 2026
- P/E
- -8.98x
- Trailing twelve months
- P/B
- 2.49x
- Latest reported equity
- P/S
- 163.88x
- Trailing twelve months
- ROE
- -27.7%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $4.1B
- As of Nov 13, 2026
- P/E
- -8.98x
- Trailing twelve months
- P/B
- 2.49x
- Latest reported equity
- P/S
- 163.88x
- Trailing twelve months
- ROE
- -27.7%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-8.98x
Net loss — not comparable
P/B
2.49x
P/S
163.88x
Earnings and dividend metrics▾
Earnings
EPS
-$4.70
Earnings per share
BPS
$16.99
Book value per share
ROE
-27.7%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $4.70 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $16.99 of net assets.
- ROE — shareholder equity shrank by 27.7% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 1,200.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $1M+1,200.0%
$1M
Jul–Sep '24
$1M
Jul–Sep '25
$13M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 2, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 1,200.0% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 2, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Kulkarni SamarthChief Executive Officer · Oct 19, 2026Open-market sale47,837 shares · $2.4MAvg. price $49.78311,899 shares held after
- Kulkarni SamarthChief Executive Officer · Oct 16, 2026Option exercise100,000 shares359,736 shares held after
- George SimeonDirector · Oct 14, 2026Open-market sale14,514 shares · $720KAvg. price $49.63315,486 shares held after
- Kulkarni SamarthChief Executive Officer · Oct 14, 2026Open-market sale4,098 shares · $202KAvg. price $49.26259,736 shares held after
- KASINGER JAMES R.General Counsel and Secretary · Oct 14, 2026Open-market sale1,040 shares · $51KAvg. price $49.2695,857 shares held after
- George SimeonDirector · Oct 14, 2026Option exercise30,000 shares · $420KAvg. price $1430,000 shares held after
- Kulkarni SamarthChief Executive Officer · Oct 13, 2026Option exercise8,333 shares263,834 shares held after
- KASINGER JAMES R.General Counsel and Secretary · Oct 13, 2026Option exercise2,113 shares96,897 shares held after
- KASINGER JAMES R.General Counsel and Secretary · Oct 6, 2026Open-market sale1,990 shares · $119KAvg. price $60.040894,784 shares held after
- KASINGER JAMES R.General Counsel and Secretary · Oct 6, 2026Option exercise1,990 shares · $27KAvg. price $13.6296,774 shares held after
- KASINGER JAMES R.General Counsel and Secretary · Sep 22, 2026Open-market sale10,400 shares · $626KAvg. price $60.236594,784 shares held after
- KASINGER JAMES R.General Counsel and Secretary · Sep 22, 2026Option exercise10,400 shares · $142KAvg. price $13.62105,184 shares held after
- Behbahani AliDirector · Sep 17, 2026Open-market sale13,679 shares · $781KAvg. price $57.090116,637 shares held after
- Behbahani AliDirector · Sep 17, 2026Option exercise30,000 shares · $420KAvg. price $1430,316 shares held after
- Prasad RajuChief Financial Officer · Aug 7, 2026Gift750 shares · $0Avg. price $014,815 shares held after
- Behbahani AliDirector · Aug 6, 2025Other75 shares · $0Avg. price $0
Show 2 price lots
- 60 shares × $0$0
- 15 shares × $0$0
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Crispr Therapeutics (CRSP) stock information
NASDAQ
Crispr Therapeutics (CRSP) is listed on NASDAQ. Its market capitalization is about $4.1B. On trailing-twelve-month earnings the P/E ratio is -8.98, and the P/B ratio is 2.49. Return on equity is -27.7%. These figures are computed in-house from official filings and are reference information only.
Crispr Therapeutics — frequently asked questions
- What is the P/E ratio of Crispr Therapeutics (CRSP)?
- On a trailing-twelve-month basis, CRSP trades at a P/E ratio of -8.98. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Crispr Therapeutics?
- CRSP has a market capitalization of about $4.1B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.